Search research articles
Contact Us
Filters
Showing results (1201-1210 of 1,272) with videos related to
Page
of 128
Sort By:
Plos One
|
April 9, 2025
Multiplexed cytokine profiling identifies diagnostic signatures for latent tuberculosis and reactivation risk stratification
Krista Meserve, Cole A Chapman, Mingrui Xu, et al.
COPD
|
February 9, 2011
Randomized trial of zileuton for treatment of COPD exacerbations requiring hospitalization
Prescott G Woodruff, Richard K Albert, William C Bailey, et al.
The New England Journal of Medicine
|
August 26, 2011
Azithromycin for prevention of exacerbations of COPD
Richard K Albert, John Connett, William C Bailey, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America
|
June 2, 2012
Long-term comparative immunogenicity of protein conjugate and free polysaccharide pneumococcal vaccines in chronic obstructive pulmonary disease
Mark T Dransfield, Sarah Harnden, Robert L Burton, et al.
Biorxiv : the Preprint Server for Biology
|
April 15, 2026
A SARS-CoV-2 entry inhibitor trimerizes to lock the spike protein in a closed conformation
Huihui Mou, Bo Gao, Gang Ye, et al.
Sensors (Basel, Switzerland)
|
May 15, 2019
Intercomparison of Small Unmanned Aircraft System (sUAS) Measurements for Atmospheric Science during the LAPSE-RATE Campaign
Lindsay Barbieri, Stephan T Kral, Sean C C Bailey, et al.
The New England Journal of Medicine
|
February 15, 2019
Decolonization to Reduce Postdischarge Infection Risk among MRSA Carriers
Susan S Huang, Raveena Singh, James A McKinnell, et al.
Nature
|
February 25, 2015
AAV-expressed eCD4-Ig provides durable protection from multiple SHIV challenges
Matthew R Gardner, Lisa M Kattenhorn, Hema R Kondur, et al.
The Lancet. HIV
|
May 29, 2025
Safety, pharmacokinetics, and neutralisation activity of PGDM1400LS, a V2 specific HIV-1 broadly neutralising antibody, infused intravenously or subcutaneously in people without HIV-1 in the USA (HVTN 140/HPTN 101 part A): a first-in-human, phase 1 randomised trial
Kelly E Seaton, Carmen A Paez, Chenchen Yu, et al.
Chest
|
May 23, 2020
Serum IgG Levels and Risk of COPD Hospitalization: A Pooled Meta-analysis
Fernando Sergio Leitao Filho, Andre Mattman, Robert Schellenberg, et al.
Page
of 128
Search research articles
Search
Showing results (1201-1210 of 1,272) with videos related to
Sort By:
Page
of 128
Plos One
|
April 9, 2025
Multiplexed cytokine profiling identifies diagnostic signatures for latent tuberculosis and reactivation risk stratification
Krista Meserve, Cole A Chapman, Mingrui Xu, et al.
COPD
|
February 9, 2011
Randomized trial of zileuton for treatment of COPD exacerbations requiring hospitalization
Prescott G Woodruff, Richard K Albert, William C Bailey, et al.
The New England Journal of Medicine
|
August 26, 2011
Azithromycin for prevention of exacerbations of COPD
Richard K Albert, John Connett, William C Bailey, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America
|
June 2, 2012
Long-term comparative immunogenicity of protein conjugate and free polysaccharide pneumococcal vaccines in chronic obstructive pulmonary disease
Mark T Dransfield, Sarah Harnden, Robert L Burton, et al.
Biorxiv : the Preprint Server for Biology
|
April 15, 2026
A SARS-CoV-2 entry inhibitor trimerizes to lock the spike protein in a closed conformation
Huihui Mou, Bo Gao, Gang Ye, et al.
Sensors (Basel, Switzerland)
|
May 15, 2019
Intercomparison of Small Unmanned Aircraft System (sUAS) Measurements for Atmospheric Science during the LAPSE-RATE Campaign
Lindsay Barbieri, Stephan T Kral, Sean C C Bailey, et al.
The New England Journal of Medicine
|
February 15, 2019
Decolonization to Reduce Postdischarge Infection Risk among MRSA Carriers
Susan S Huang, Raveena Singh, James A McKinnell, et al.
Nature
|
February 25, 2015
AAV-expressed eCD4-Ig provides durable protection from multiple SHIV challenges
Matthew R Gardner, Lisa M Kattenhorn, Hema R Kondur, et al.
The Lancet. HIV
|
May 29, 2025
Safety, pharmacokinetics, and neutralisation activity of PGDM1400LS, a V2 specific HIV-1 broadly neutralising antibody, infused intravenously or subcutaneously in people without HIV-1 in the USA (HVTN 140/HPTN 101 part A): a first-in-human, phase 1 randomised trial
Kelly E Seaton, Carmen A Paez, Chenchen Yu, et al.
Chest
|
May 23, 2020
Serum IgG Levels and Risk of COPD Hospitalization: A Pooled Meta-analysis
Fernando Sergio Leitao Filho, Andre Mattman, Robert Schellenberg, et al.
Page
of 128